⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23872671 | 0.79 | — | — | |
| SCHEMBL25096101 | 0.79 | — | — | |
| SCHEMBL777596 | 0.76 | — | — | |
| SCHEMBL23872674 | 0.75 | — | — | |
| SCHEMBL21789765 | 0.73 | — | — | |
| SCHEMBL25927528 | 0.73 | — | — | |
| SCHEMBL23872393 | 0.72 | — | — | |
| SCHEMBL25927626 | 0.72 | — | — | |
| SCHEMBL14892197 | 0.71 | — | — | |
| SCHEMBL19413966 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2023125928-A1 | MENIN INHIBITOR AND USE THEREOF | 成都先导药物开发股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20230159543-A1 | ANTHELMINTIC PYRROLOPYRIDAZINE COMPOUNDS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-9115100-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150197494-A1 | NO-RELEASING NITROOXY-METHYLENE-LINKED-COXIB CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150105361-A1 | METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE AND POLYCYSTIC LIVER DISEASE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150005493-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. | 2015-01-01 | — | — | US | disclosed |
| US-8853210-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140088304-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8497396-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8178490-B2 | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100256366-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. | 2010-10-07 | — | — | US | disclosed |
| CN-1383425-A | Uracil substituted phenyl sulfamoyl carboxamides | BASF AG (DE) | 2002-12-04 | — | — | CN | disclosed |